Detalhe da pesquisa
1.
PRKCI promotes immune suppression in ovarian cancer.
Genes Dev
; 31(11): 1109-1121, 2017 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28698296
2.
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
Gynecol Oncol
; 187: 105-112, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38759516
3.
Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue.
Gynecol Oncol
; 177: 165-172, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708581
4.
Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted Agents.
Cancer Treat Res
; 186: 171-188, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37978136
5.
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
Br J Cancer
; 126(7): 1027-1036, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34887522
6.
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.
Gynecol Oncol
; 160(1): 322-332, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33160694
7.
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Gynecol Oncol
; 162(2): 482-495, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34090705
8.
Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.
Gynecol Oncol
; 160(1): 227-233, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33190931
9.
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
Gynecol Oncol
; 163(2): 254-261, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34474927
10.
Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors.
Gynecol Oncol
; 161(2): 581-586, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33637350
11.
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
Gynecol Oncol
; 156(2): 488-497, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31630846
12.
Clinical assays for assessment of homologous recombination DNA repair deficiency.
Gynecol Oncol
; 159(3): 887-898, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33012552
13.
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.
Gynecol Oncol
; 158(1): 16-24, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32386911
14.
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Gynecol Oncol
; 158(3): 631-639, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32534811
15.
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Gynecol Oncol
; 159(1): 72-78, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32771276
16.
Antibody-drug conjugates in gynecologic malignancies.
Gynecol Oncol
; 153(3): 694-702, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30929824
17.
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
Gynecol Oncol
; 154(1): 95-101, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31118140
18.
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
Gynecol Oncol
; 154(2): 314-322, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31204078
19.
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).
Int J Gynecol Pathol
; 38(3): 230-240, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29750700
20.
One fixed dosing of a poly(adenosine diphosphate ribose) polymerase inhibitor does not fit all.
Cancer
; 129(12): 1795-1796, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37060235